Myriad Genetics, Inc.

Equities

MYGN

US62855J1043

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq 03:59:51 2024-02-22 pm EST 5-day change 1st Jan Change
23.1 USD +0.81% Intraday chart for Myriad Genetics, Inc. -2.10% +20.66%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Myriad Genetics Acquires Intermountain Precision Genomics' Assets from Intermountain Health MT
Myriad Genetics, Inc. acquired Select assets Intermountain Precision Genomics. CI
Myriad Genetics Names George Daneker Jr. as President, Chief Clinical Officer of Oncology MT
Myriad Genetics, Inc. Appoints George Daneker as President and Chief Clinical Officer of Oncology, Effective March 18, 2024 CI
Goldman Sachs Adjusts Myriad Genetics' Price Target to $31 From $28, Maintains Buy Rating MT
BofA Securities Adjusts Price Target on Myriad Genetics to $20 From $18, Maintains Underperform Rating MT
Myriad Genetics Agrees to Acquire Select Assets of Intermountain Precision Genomics' Laboratory Business MT
Myriad Genetics, Inc. agreed to acquire Select assets of Intermountain Health Care, Inc. CI
Transcript : Myriad Genetics, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 04:30 PM
Certain Common Stock of Myriad Genetics, Inc. are subject to a Lock-Up Agreement Ending on 8-JAN-2024. CI
Certain Restricted Stock Units of Myriad Genetics, Inc. are subject to a Lock-Up Agreement Ending on 8-JAN-2024. CI
Certain Options of Myriad Genetics, Inc. are subject to a Lock-Up Agreement Ending on 8-JAN-2024. CI
Myriad Genetics, Inc. Announces Chief Financial Officer Changes CI
Myriad Genetics Names Scott Leffler as Chief Financial Officer, Reiterates Outlook MT
Wells Fargo Initiates Myriad Genetics at Equalweight Rating With $20 Price Target MT
Wolfe Research Initiates Myriad Genetics With Outperform Rating With $28 Price Target MT
Myriad Genetics, Personalis Collaborate to Market ImmunoID NeXT Platform MT
Myriad Genetics, Inc. and Personalis, Inc. Partner to Market Solutions to Pharma Customers CI
Myriad Genetics Shares Climb as Q3 Loss Narrower Than Estimated, FY Revenue Guidance Raised MT
Tranche Update on Myriad Genetics, Inc.'s Equity Buyback Plan announced on November 5, 2013. CI
Transcript : Myriad Genetics, Inc., Q3 2023 Earnings Call, Nov 06, 2023
(MYGN) MYRIAD GENETICS Forecasts Fiscal Year 2023 Revenue Range $747M - $753M MT
Earnings Flash (MYGN) MYRIAD GENETICS Posts Q3 Revenue $191.9M, vs. Street Est of $196.1M MT
Earnings Flash (MYGN) MYRIAD GENETICS Reports Q3 EPS $-0.03, vs. Street Est of $-0.02 MT
Myriad Genetics, Inc. Provides Financial Guidance for 2023 and 2024 CI
Chart Myriad Genetics, Inc.
More charts
Myriad Genetics, Inc.is a genetic testing and precision medicine company. The Company provides testing that helps assess an individual's risk for developing disease or disease progression and guides treatment decisions across medical specialties where genetic insights can significantly improve patient health care and lower health care costs, and includes corporate services, such as finance, human resources, legal and information technology. It has three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test which can reveal a baby's gender as early as six weeks into pregnancy. Its products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, and EndoPredict, Foresight, Prequel, and SneakPeek and GeneSight.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
12
Last Close Price
23.1 USD
Average target price
22.5 USD
Spread / Average Target
-2.60%
Consensus
  1. Stock
  2. Equities
  3. Stock Myriad Genetics, Inc. - Nasdaq
  4. News Myriad Genetics, Inc.
  5. BofA Securities Trims Price Target on Myriad Genetics to $18 From $21, Maintains Underperform Rating
+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019
Replicate our performance
fermer